Progress on many fronts- Targeting tumours with the newest technologies on offer

 There is a lot more for immunotherapy to do in future cancer care....  The Economist has just released the  Technology Quarterly  which has provided a detailed insight into the current state-of-the-art in cancer care.   IMMUNOTHERAPY has been featured for its huge promise, both as an addition to established therapies and as a foundation for future ones. The importance of genetic screening of patient's tumours has also been highlighted. OvaCure believes that the cure to ovarian cancer lies in the tumour itself. We stand by these new cutting-edge technologies, which will uncover the secrets of the tumour, leading to curative treatment options for patients.   

There is a lot more for immunotherapy to do in future cancer care....

The Economist has just released the Technology Quarterly which has provided a detailed insight into the current state-of-the-art in cancer care. 

IMMUNOTHERAPY has been featured for its huge promise, both as an addition to established therapies and as a foundation for future ones. The importance of genetic screening of patient's tumours has also been highlighted. OvaCure believes that the cure to ovarian cancer lies in the tumour itself. We stand by these new cutting-edge technologies, which will uncover the secrets of the tumour, leading to curative treatment options for patients.